Loading...

Duality Biotherapeutics, Inc.

9606.HK•HKSE
Healthcare
Biotechnology
HK$287.80
HK$1.40(0.49%)

Duality Biotherapeutics, Inc. (9606.HK) Stock Overview

Explore Duality Biotherapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

C+

Score: 57.5/100

Key Financials

Market Cap25.3B
P/E Ratio0.00
EPS (TTM)$-13.82
ROE0.41%
Fundamental Analysis

AI Price Forecasts

1 Week$210.09
1 Month$210.26
3 Months$261.97
1 Year TargetN/A

9606.HK Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Duality Biotherapeutics, Inc. (9606.HK) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of C+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 64.17, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of N/A.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 0.00 and a market capitalization of 25.3B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

64.17RSI (14)
14.42MACD
33.78ADX
Stats data is not available for 9606.HKStats details for 9606.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for 9606.HKAnalyst Recommendations details for 9606.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Duality Biotherapeutics, Inc. operates as a clinical stage company. It focuses on the development of next generation antibody-drug conjugate therapeutics and duality immune toxin antibody conjugate therapeutic. The company was founded by Zhu Zhong Yuan on July 3, 2019 and is headquartered in Shanghai, China.

Employees

170

Headquarters

Units 1103-1106, Building A, 868 Yinghua Road, Shanghai

Founded

2025

Frequently Asked Questions

;